AstraZeneca plans to invest 650 million pounds ($826.80 million) in Britain to boost research, development and manufacturing of vaccines, the government announced on Wednesday as part of Finance Mi...

Chancellor Jeremy Hunt also announced that British pharma giant AstraZeneca PLC (LSE:AZN) plans to invest £650 million in UK life sciences. Under levelling-up plans, AstraZeneca will develop a vacc...

In the closing of the recent trading day, Astrazeneca (AZN) stood at $64.60, denoting a +0.69% change from the preceding trading day.

U.S. District Judge Colm Connolly's decision comes one day before manufacturers have to respond to Medicare's initial price offers for their drugs.

Even after aggressive contractionary monetary policies by the federal reserve, inflation has remained relatively stubborn. Supply-chain issues and an increase in price of agricultural commodities a...

FibroGen Inc said on Monday it is regaining rights to the anemia drug, roxadustat, from AstraZeneca after the companies mutually agreed to terminate their collaboration agreement.

Greg Rossi, senior vice president of oncology in Europe and Canada at AstraZeneca, discusses the company's three announcements on lung cancer drugs and treatments.

AstraZeneca's (LON: AZN) stock surged on the FTSE 100 index following the announcement of the approval of its lung-cancer drug Tagrisso, in combination with chemotherapy. AstraZaneca's shares were ...

AstraZeneca PLC (LSE:AZN) is set to see a sales boost from new lung cancer treatments, according to UBS analysts, after the pharmaceuticals firm updated on two treatments on Monday. UBS anticipated...

AstraZeneca PLC (LSE:AZN) shares swung 4% higher on Monday after it emerged that blockbuster drug Tagrisso (osimertinib), with the addition of chemotherapy, has been approved in the US for the trea...

A combination of AstraZeneca's blockbuster cancer drug Tagrisso with chemotherapy to treat a type of lung cancer has been approved by the U.S. Food and Drug Administration (FDA), the company said i...

Finding good, bargain-priced stocks is difficult in a market regularly hitting new all-time highs. Although you can buy many cheap stocks, they are cheap for a reason.

AstraZeneca PLC (LSE:AZN) was among the FTSE 100's big fallers on Monday as debate raged on around the company's year-end earnings late last week. AstraZeneca found itself still reeling from what t...

AstraZeneca PLC (LSE:AZN) faced a blow on Friday after Deutsche Bank analysts downgraded the pharmaceuticals giant on what they labelled a “thoroughly disappointing” end to 2023. Analysts wrote in ...